Add like
Add dislike
Add to saved papers

Intraocular Concentrations of Cytokines and Chemokines in a Unique Case of Nivolumab-Induced Uveitis.

PURPOSE: To report a unique case of nivolumab-induced uveitis and the results of a cytokine analysis of an intraocular fluid sample.

CASE REPORT: A 61-year-old male patient undergoing treatment for renal cell carcinoma with nivolumab presented with bilateral uveitis. Severe anterior uveitis and vitreous opacity coincided with decreased visual acuity only in his left eye. Iris damage was present in this eye because of previous complicated cataract surgery. Vitrectomy was performed to remove the vitreous opacity, and visual acuity recovered postoperatively. A cytokine analysis of an intraocular fluid sample revealed a high level of interleukin-6, granulocyte-colony stimulating factor and interferon-inducible protein-10.

CONCLUSION: This case indicates that nivolumab-induced uveitis might be more severe in eyes with a damaged iris, and that vitrectomy should be effective for vitreous opacity. A cytokine analysis of the ocular fluid indicated that multiple types of cell might be related to the inflammation process.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app